$AVR

Anteris Technologies Global Corp. (AVR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Contingent Grant of Nonqualified Stock Options to Wayne Paterson and David St Denis On September 12, 2026, Anteris Technol

Original reporting
Published Sep 17, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

The filing provides transparency on executive compensation but is unlikely to move the stock significantly.

02

Market read

Primary disclosure of new equity compensation; limited trading relevance for AVR shareholders.

03

What to watch

Potential change‑in‑control provisions could accelerate vesting, affecting future dilution if a merger occurs.

Relevance 6/10Novelty 4/10Timing: filed Sep 17 2026

Background

Anteris Technologies Global Corp. filed an 8‑K reporting new contingent equity awards to senior officers, a routine corporate governance disclosure.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

SEC 8‑K filing discloses new contingent stock option and PSU grants to senior officers, a material compensation event for the company.

Expected impact

Limited short‑term price movement; potential slight downside pressure as dilution risk is priced in.

Evidence & confidence

Compensation filings are routine for micro‑caps; market typically reacts modestly unless the grant size is large, which is not the case here.

Market effects

Minimal impact on the broader biotech/health‑tech sector; compensation practices are standard.

No regional effect; the filing pertains only to the company.

Low global relevance; limited to shareholders of AVR.

Counterpoint

If the granted options are exercised at higher stock prices, dilution could be offset by performance‑driven upside.

Key entities

  • Wayne Paterson

    Recipient of 1.2M stock options and 800k PSUs.

  • David St Denis

    Recipient of 414k stock options and 485k PSUs.

  • Matthew McDonnell

    Recipient of $500k worth of non‑qualified stock options.

Related articles

$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.